Introduction 

In the intricate landscape of emerging infectious diseases, Mojiang Heniparvirus has emerged as a novel pathogen, capturing the attention of researchers and public health experts worldwide. Belonging to the Henipavirus genus, alongside well-known viruses like Nipah and Hendra, Mojiang Heniparvirus presents a complex clinical picture with symptoms ranging from mild febrile illness to severe respiratory and neurological manifestations

Against the backdrop of the evolving landscape of infectious diseases, Mojiang Heniparvirus serves as a poignant reminder of the dynamic interplay between humans, animals, and the environment. As the global community continues to grapple with the ongoing challenges posed by infectious diseases, this article aims to provide a comprehensive exploration of Mojiang Heniparvirus symptoms, shedding light on its clinical manifestations, diagnostic challenges, epidemiology, prevention strategies, and ongoing research efforts

Background on mojiang henipavirus 

Genus and family 

To contextualise the Moijang heniparvirus, the definitions of a genus and family require comprehension. The prior encompasses a category ranking above the species level and below the family level. Organisms are categorised into this group based on a common characteristic present that differentiates them from other genera within the same family.¹ Subsequently, the latter ranks below the order and above the genus, whereby members of the same family are more closely related to each other than they are to other members of the same order.¹

The Moijang heniparvirus belongs to the genus Heniparvirus and the family of Paramyxoviridae, alongside seven other members including Hendra, Nipah, Cedar, Gamak, Daeryong, Kumasi and novel Angavokely and Langya viruses. 

Discovery and geographical distributions

Generally, the names of henipaviruses are all taken from the places of discovery. For instance, the Hendra virus was first found in Hendra Town, Australia; the Nipah virus (NiV) was first found in Nipah New Town, Malaysia; the Mojiang virus was first found in Mojiang County, China; the Angavokely virus was first found in Angavokely, Madagascar; and Langya virus was first found in Langya Town, China.²

The geographical distribution of the viruses is widespread, ranging from the discovery of the first Heniparvirus in Western Australia in 1994 to the emergence of NiV during a 1998–1999 outbreak in peninsular Malaysia and Singapore.² Since this period, there have been annual outbreaks of NiV in Bangladesh or Western Bengal, India, as well as Kerala on the western coast, demonstrating the widespread distribution of this virus across the Indian subcontinent.²

Transmission

The Henipavirus genus has been proposed to have zoonotic transmission, whereby the virus is passed from animals to humans, thus this process is where the scientific research has focused their target for therapeutic interventions and precautionary measures.³ However, the Mojiang Heniparvirus specifically, has no direct evidence of causing disease in humans in light of the isolation of viral RNA from rat rectal swabs from rats caught in a mine, where three workers acquired fatal pneumonia of unknown origin.³ 

Symptoms 

Although the Mojiang virus does currently not cause direct symptoms in humans, NiV and HeV are highly virulent pathogens that cause outbreaks in humans and are associated with high case-fatality ratios.⁴ 

The Incubation period of HeV and NiV is roughly 5–16 days (rarely ≤2 months). Both viral infections can cause a severe influenza-like illness with accompanying dizziness, headache, fever, and myalgias (muscle pain)(4). Due to the high virility of these viruses, they replicate rapidly in the primary target site of the trachea, causing severe respiratory symptoms and potentially acute respiratory distress syndrome.² The disease can progress to severe encephalitis (inflammation of the brain tissue) with confusion, abnormal reflexes, seizures, and coma.⁴ Dissemination of this virus into the bloodstream can result in multiple organ failure including the lungs, spleen kidneys and brain.²

Aside from acute manifestations, relapsing or late-onset encephalitis can occur months or years after initial illness presentation.⁴ The case-fatality ratio of Hendra virus is 57%; among 7 known human cases, with 4 resulting in fatality. Case-fatality ratios for Nipah virus infection are 40%–70% but have been 100% in some human outbreaks.⁴

Diagnosis 

A clinical diagnosis of Henipavirus infection is laboratory based, made by using a combination of tests, including an ELISA of serum or cerebrospinal fluid (CSF), reverse transcription polymerase chain reaction of serum, CSF, or throat swabs, and virus isolation from CSF or throat swabs (4).

Treatment and management 

No specific antiviral treatment is available for Henipavirus infections,⁴ however, various antiviral therapies may be utilised on a compassionate basis in the case of outbreaks.² Ribavirin has shown in vitro effectiveness, and elicited a 36% reduction in mortality rates in a cohort study of patients treated with Ribavirin, however no statistically significant relationship could be established between treatment and prognosis.²

Management of this infection consists of supportive care and treatment of complications, rather than tackling the causative agent.⁴

Preventative measures

As no specific transmission route has been identified for the Mojiang Henipavirus, there are no current preventative measures institutionalised. However, for HeV and NiV, the public should be cautious whilst travelling and avoid contact with bats, sick horses and pigs, and their excretions.⁴ The CDC additionally advocated that travellers should not consume fallen fruit, raw date palm sap, or products made from raw sap.⁴

Conclusion 

The exploration of Mojiang Henipavirus symptoms sheds light on the intricate nature of emerging infectious diseases and underscores the importance of vigilance, collaboration, and innovation in addressing global health threats. Through our examination of the clinical manifestations, diagnostic complexities, epidemiological patterns, and management strategies of Henipavirus, we have gained valuable insights into the dynamic interplay between pathogens, hosts, and the environment

As we navigate the evolving landscape of infectious diseases, Mojiang Henipavirus serves as a poignant reminder of the ongoing challenges posed by transmission risks and the interconnectedness of human, animal, and environmental health. Moving forward, continued surveillance, research, and collaboration are essential in enhancing our preparedness and response capabilities against emerging infectious diseases like Mojiang Henipavirus.